Cost effectiveness analysis of erythropoietin therapy in the ministry of health dialysis programme
End-stage renal failure patients are normally anaemic due to failure of renal to produce endogenous erythropoietin (EPO). Erythropoietin is used to treat anaemia in these patients but the drug is expensive. The drug is also used in cancer and thalassemia patients and it makes EPO in high demand and...
محفوظ في:
المؤلف الرئيسي: | |
---|---|
التنسيق: | أطروحة |
اللغة: | English |
منشور في: |
2006
|
الموضوعات: | |
الوصول للمادة أونلاين: | http://eprints.usm.my/51024/1/Cost%20effectiveness%20analysis%20of%20erythropoietin%20therapy%20in%20the%20ministry%20of%20health%20dialysis%20programme24.pdf |
الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|